Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19261330 | 0.71 | MEN1 (0.42) | CYP3A4CYP19A1MEN1POLBKMT2A | |
| SCHEMBL6995592 | 0.70 | — | — | |
| SCHEMBL26134441 | 0.69 | CYP19A1 (0.36) | CYP3A4CYP19A1MEN1POLBKMT2A | |
| SCHEMBL12820352 | 0.68 | CYP3A4 (0.39) | CYP3A4CYP19A1MAPT | |
| SCHEMBL15998896 | 0.66 | — | — | |
| SCHEMBL15983848 | 0.66 | MEN1 (0.38) | CYP3A4CYP19A1MEN1POLBKMT2A | |
| SCHEMBL179558 | 0.65 | — | — | |
| SCHEMBL26576428 | 0.64 | CYP19A1 (0.38) | CYP3A4CYP19A1MEN1POLBKMT2A | |
| SCHEMBL25627095 | 0.64 | MEN1 (0.40) | CYP3A4CYP19A1MEN1POLBKMT2A | |
| SCHEMBL21369511 | 0.64 | MEN1 (0.40) | CYP3A4CYP19A1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | BioVersys AG (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | MELINTA THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | CYP3A4 1726/4885CYP19A1 2966/4885MEN1 4100/4885 |
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | CYP3A4 1726/4885CYP19A1 2966/4885MEN1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.